Quantitative analysis of phospholipids containing arachidonate and docosahexaenoate chains in microdissected regions of mouse brain

Journal of Lipid Research

Volumn 51, Issue 3, 2010, Pages 660-671

  Axelsen, Paul H ^a   Murphy, Robert C ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Alzheimer's disease; Negative mode MS; Normalphase HPLC; Oxidative stress; Plasmalogen

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; GLYCEROPHOSPHOETHANOLAMINE; GLYCEROPHOSPHOLIPID; GLYCEROPHOSPHORYLCHOLINE; GLYCEROPHOSPHORYLGLYCEROL; GLYCEROPHOSPHORYLINOSITOL; GLYCEROPHOSPHORYLSERINE; PHOSPHATIDIC ACID; PHOSPHOLIPID; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN REGION; BRAIN TISSUE; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; GAS CHROMATOGRAPHY; HIPPOCAMPUS; ISOTOPE DILUTION ASSAY; LIPID BRAIN LEVEL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICRODISSECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY;

ALZHEIMER DISEASE; ANIMALS; ARACHIDONIC ACID; BRAIN; CHEMICAL FRACTIONATION; DOCOSAHEXAENOIC ACIDS; FEMALE; MASS SPECTROMETRY; MICE; MICRODISSECTION; OXIDATIVE STRESS; PHOSPHOLIPIDS;

EID: 77950608367     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.D001750     Document Type: Article

References (61)

1. Montine, T. J., M. D. Neely, J. F. Quinn, M. F. Beal, W. R. Markesbery, L. J. Roberts, and J. D. Morrow. 2002. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic. Biol. Med. 33: 620-626.
2. Pratico, D., V. M. Y. Lee, J. Q. Trojanowski, J. Rokach, and G. A. FitzGerald. 1998. Increased F-2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 12: 1777-1783.
3. Montine, T. J., K S. Montine, W. McMahan, W. R. Markesbery, J. F. Quinn, and J. D. Morrow. 2005. F-2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid. Redox Signal. 7: 269-275.
4. Sayre, L. M., D. A. Zelasko, P. L. R. Harris, G. Perry, R. G. Salomon, and M. A. Smith. 1997. 4-hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68: 2092-2097.
5. Ando, Y., T. Brannstrom, K Uchida, N. Nyhlin, B. Nasman, O. Suhr, T. Yamashita, T. Olsson, M. El Salhy, M. Uchino, et al. 1998. Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. J. Neurol. Sci. 156: 172-176.
6. Markesbery, W. R., and M. A. Lovell. 1998. Four-Hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging. 19: 33-36.
7. Murray, I. V. J., M. E. Sindoni, and P. H. Axelsen. 2005. Promotion of oxidative lipid membrane damage by amyloid beta proteins. Biochemistry. 44: 12606-12613.
8. Koppaka, V., and P. H. Axelsen. 2000. Accelerated accumulation of amyloid beta proteins on oxidatively damaged lipid membranes. Biochemistry. 39: 10011-10016.
9. Koppaka, V., C. Paul, I. V. J. Murray, and P. H. Axelsen. 2003. Early synergy between A|342 and oxidatively damaged membranes in promoting amyloid fibril formation by A|340. J. Biol. Chem. 278: 36277-36284.
10. Komatsu, H., L. Liu, I. V. Murray, and P. H. Axelsen. 2007. A mechanistic link between oxidative stress and membrane mediated amyloidogenesis revealed by infrared spectroscopy. Biochim Biophys Acta. 1768: 1913-1922.
11. Murray, I. V. J., L. Liu, H. Komatsu, K Uryu, G. Xiao, J. A. Lawson, and P. H. Axelsen. 2007. Membrane mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta proteins. J. Biol. Chem. 282: 9335-9345.
12. Kyle, D. J., E. Schaefer, G. Patton, and A. Beiser. 1999. Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Lipids. 34: S245.
13. Morris, M. C. 2006. Docosahexaenoic acid and Alzheimer disease. Arch. Neurol. 63: 1527-1528.
14. Schaefer, E. J., V. Bongard, A. S. Beiser, S. Lamon-Fava, S. J. Robins, R Au, K L. Tucker, D. J. Kyle, P. W. F. Wilson, and P. A. Wolf. 2006. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease-The Framingham heart study. Arch. Neurol. 63: 1545-1550.
15. Tully, A. M., H. M. Roche, R. Doyle, C. Fallon, I. Bruce, B. Lawlor, D. Coakley, and M. J. Gibney. 2003. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br. J. Nutr. 89: 483-489.
16. Morris, M. C., D. A. Evans, J. L. Bienias, C. C. Tangney, D. A. Bennett, R S. Wilson, N. Aggarwal, and J. Schneider. 2003. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 60: 940-946.
17. Barberger-Gateau, P., C. Raffaitin, L. Letenneur, C. Berr, C. Tzourio, J. F. Dartigues, and A. Alperovitch. 2007. Dietary patterns and risk of dementia: the three-city cohort study. Neurology. 69: 1921-1930.
18. Calon, F., G. P. Lim, T. Morihara, F. S. Yang, O. Ubeda, N. Salem, S. A. Frautschy, and G. M. Cole. 2005. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur. J. Neurosci. 22: 617-626.
19. Calon, F., G. P. Lim, F. S. Yang, T. Morihara, B. Teter, O. Ubeda, P. Rostaing, A. Triller, N. Salem, K H. Ashe, et al. 2004. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron. 43: 633-645.
20. Lim, G. P., F. Calon, T. Morihara, F. S. Yang, B. Teter, O. Ubeda, N. Salem, S. A. Frautschy, and G. M. Cole. 2005. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 25: 3032-3040.
21. Calon, F., and G. Cole. 2007. Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukot. Essent. Fatty Acids. 77: 287-293.
22. Calderon, F., and H. Y Kim. 2004. Docosahexaenoic acid pro-motes neurite growth in hippocampal neurons. J. Neurochem. 90: 979-988.
23. Green, K N., H. Martinez-Coria, H. Khashwji, E. B. Hall, K A. Yurko-Mauro, L. Ellis, and F. M. LaFerla. 2007. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J. Neurosci. 27: 4385-4395.
24. DeMar, J. C, K Z. Ma, J. M. Bell, and S. I. Rapoport. 2004. Half-lives of docosahexaenoic acid in rat brain phospholipids are prolonged by 15 weeks of nutritional deprivation of n-3 polyunsaturated fatty acids. J. Neurochem. 91: 1125-1137.
25. Plourde, M., M. Fortier, M. Vandal, J. Tremblay-Mercier, E. Freemantle, M. Begin, F. Pifferi, and S. C. Cunnane. 2007. Unresolved issues in the link between docosahexaenoic acid and Alzheimer's disease. Prostaglandins Leukot. Essent. Fatty Acids. 77: 301-308.
26. Arendash, G. W., M. T. Jensen, N. Salem, N. Hussein, J. Cracchiolo, A. Dickson, R. Leighty, and H. Potter. 2007. A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice. Neuroscience. 149: 286-302.
27. Liu, L., H. Komatsu, I. V. J. Murray, and P. H. Axelsen. 2008. Promotion of amyloid |3 protein misfolding and fibrillogenesis by a lipid oxidation product. J. Mol. Biol. 377: 1236-1250.
28. Yamamoto, A., and G. Rouser. 1973. Free fatty-acids of normal hu-man whole brain at different ages. J. Gerontol. 28: 140-142.
29. Ulmann, L., V. Mimouni, S. Roux, R. Porsolt, and J. P. Poisson. 2001. Brain and hippocampus fatty acid composition in phospholipid classes of aged relative cognitive deficit rats. Prostaglandins Leukot. Essent. Fatty Acids. 64: 189-195.
30. Prasad, M. R., M. A. Lovell, M. Yatin, H. Dhillon, and W. R Markesbery. 1998. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 23: 81-88. (Pubitemid 28145695)
31. Rouzer, C. A., P. T. Ivanova, M. O. Byrne, H. A. Brown, and L. J. Marnett. 2007. Lipid profiling reveals glycerophospholipid remodeling in zymosan-stimulated macrophages. Biochemistry. 46: 6026-6042.
32. Han, X., D. M. Holtzman, and D. W. McKeel. 2001. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 77: 1168-1180.
33. Goodenowe, D. B., L. L. Cook, J. Liu, Y. Lu, D. A. Jayasinghe, P. W. K Ahiahonu, D. Heath, Y. Yamazaki, J. Flax, K F. Krenitsky, et al. 2007. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J. Lipid Res. 48: 2485-2498.
34. Kayganich, K, and R. C. Murphy. 1991. Molecular-species analy-sis of arachidonate containing glycerophosphocholines by tandem mass-spectrometry. J. Am. Soc. Mass Spectrom. 2: 45-54.
35. Cheng, H., D. J. Mancuso, X. T. Jiang, S. P. Guan, J. Y Yang, K Yang, G. Sun, R. W. Gross, and X. L. Han. 2008. Shotgun lipidom-ics reveals the temporally dependent, highly diversified cardiolipin profile in the mammalian brain: Temporally coordinated postnatal diversification of cardiolipin molecular species with neuronal remodeling. Biochemistry. 47: 5869-5880.
36. Kim, H. Y 2007. Novel metabolism of docosahexaenoic acid in neural cells. J. Biol. Chem. 282: 18661-18665.
37. Brugger, B., G. Erben, R. Sandhoff, F. T. Wieland, and W. D. Lehmann. 1997. Quantitative analysis of biological membrane lipids at the low picomole level by nano-electrospray ionization tandem mass spectrometry. Proc. Natl. Acad. Sci. USA. 94: 2339-2344.
38. Farooqui, A. A., and L. A. Horrocks. 2001. Plasmalogens: work-horse lipids of membranes in normal and injured neurons and glia. Neuroscientist. 7: 232-245.
39. Jones, C. R., T. Arai, J. M. Bell, and S. I. Rapoport. 1996. Preferential in vivo incorporation of [H-3]arachidonic acid from blood into rat brain synaptosomal fractions before and after cholinergic stimulation. J. Neurochem. 67: 822-829.
40. Ginsberg, L., S. Rafique, J. H. Xuereb, S. I. Rapoport, and N. L. Gershfeld. 1995. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in alzheimers-disease brain. Brain Res. 698: 223-226.
41. Farooqui, A. A., S. I. Rapoport, and L. A. Horrocks. 1997. Membrane phospholipid alterations in Alzheimer's disease: Deficiency of etha-nolamine plasmalogens. Neurochem. Res. 22: 523-527.
42. Guan, Z., Y. A. Wang, N. J. Cairns, P. L. Lantos, G. Dallner, and P. J. Sindelar. 1999. Decrease and structural modifications of phos- phatidylethanolamine plasmalogen in the brain with Alzheimer disease. J. Neuropathol. Exp. Neurol. 58: 740-747.
43. Eriksen, J. L., and C. G. Janus. 2007. Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav. Genet. 37: 79-100.
44. Reiss, D., K. Beyer, and B. Engelmann. 1997. Delayed oxidative deg-radation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro. Biochem. J. 323: 807-814.
45. Hahnel, D., K. Beyer, and B. Engelmann. 1999. Inhibition of per-oxyl radical-mediated lipid oxidation by plasmalogen phospho-lipids and alpha-tocopherol. Free Radic. Biol. Med. 27: 1087-1094. (Pubitemid 29507481)
46. Hahnel, D., T. Huber, V. Kurze, K. Beyer, and B. Engelmann. 1999. Contribution of copper binding to the inhibition of lipid oxidation by plasmalogen phospholipids. Biochem. J. 340: 377-383. (Pubitemid 29286555)
47. Maeba, R., Y. Sawada, H. Shimasaki, I. Takahashi, and N. Ueta. 2002. Ethanolamine plasmalogens protect cholesterol-rich liposo-mal membranes from oxidation caused by free radicals. Chem. Phys. Lipids. 120: 145-151.
48. Maeba, R., and N. Ueta. 2003. Ethanolamine plasmalogens prevent the oxidation of cholesterol by reducing the oxidizability of cholesterol in phospholipid bilayers. J. Lipid Res. 44: 164-171.
49. Morandat, S., M. Bortolato, G. Anker, A. Doutheau, M. Lagarde, J. P. Chauvet, and B. Roux. 2003. Plasmalogens protect unsaturated lipids against UV-induced oxidation in monolayer. Biochim. Biophys. Acta. 1616: 137-146.
50. Kuczynski, B., and N. V. Reo. 2006. Evidence that plasmalogen is protective against oxidative stress in the rat brain. Neurochem. Res. 31: 639-656.
51. Brosche, T., and D. Platt. 1998. Mini-review: the biological signif-icance of plasmalogens in defense against oxidative damage. Exp. Gerontol. 33: 363-369.
52. Khaselev, N., and R. C. Murphy. 1999. Susceptibility of plasmenyl glycerophosphoethanolamine lipids containing arachidonate to oxidative degradation. Free Radic. Biol. Med. 26: 275-284.
53. Khaselev, N., and R. C. Murphy. 2000. Structural characterization of oxidized phospholipid products derived from arachidonate-contain-ing plasmenyl glycerophosphocholine. J. Lipid Res. 41: 564-572.
54. Khaselev, N., and R. C. Murphy. 2000. Peroxidation of arachido-nate containing plasmenyl glycerophosphocholine: Facile oxidation of esterified arachidonate at carbon-5. Free Radic. Biol. Med. 29: 620-632.
55. Murphy, R. C. 2001. Free-radical-induced oxidation of arachidonoyl plasmalogen phospholipids: Antioxidant mechanism and precursor pathway for bioactive eicosanoids. Chem. Res. Toxicol. 14: 463-472.
56. Ginsberg, L., J. H. Xuereb, and N. L. Gershfeld. 1998. Membrane instability, plasmalogen content, and Alzheimer's disease. J. Neurochem. 70: 2533-2538.
57. Zubenko, G. S. 1986. Hippocampal membrane alteration in Alzheimers disease. Brain Res. 385: 115-121.
58. Cheng, H., J. Xu, D. W. McKeel, and X. Han. 2003. Specificity and potential mechanism of sulfatide deficiency in Alzheimer's disease: an electrospray ionization mass spectrometric study. Cell. Mol. Biol. 49: 809-818.
59. Murray, I. V. J., B. I. Giasson, S. M. Quinn, V. Koppaka, P. H. Axelsen, H. Ischiropoulos, J. Q. Trojanowski, and V. M. Y. Lee. 2003. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry. 42: 8530-8540.
60. Zemski Berry, K. A., and R. C. Murphy. 2005. Free radical oxidation of plasmalogen glycerophosphocholine containing esterified doco-sahexaenoic acid: structure determination by mass spectrometry. Antioxid. Redox Signal. 7: 157-169.
61. Davis, T. A., L. Gao, H. Yin, J. D. Morrow, and N. A. Porter. 2006. In vivo and in vitro lipid peroxidation of arachidonate esters: the effect of fish oil co-3 lipids on product distribution. J. Am. Chem. Soc. 128: 14897-14904.